# Symphogen A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symphogen-a-s

- Industry: Biotechnology
- Headquarters: Denmark
- Website: www.symphogen.com
- Total disclosed funding: $57M
- Latest round: Series E (Jan 31, 2007)
- Investors on record: 7

## About

Symphogen A/S is a biotechnology company based in Denmark that focuses on developing innovative antibody therapies for oncology and immune oncology, aiming to address challenges in cancer treatment.Founded in 2000, Symphogen A/S specializes in the development of antibody therapies targeting cancer. The company has undergone various strategic pivots over the years, enhancing its focus on oncology. As of now, it operates its headquarters in Denmark and has undertaken a total of 11 deals. The latest funding round was a VENTURE DEBT round amounting to EUR 67.50 mn, led by investors Novo Holdings and PKA. To date, Symphogen has raised a total of EUR 41.00 mn. Kirsten Drejer serves as the CEO.Symphogen specializes in developing innovative antibody therapies primarily for oncology and immune oncology. The company has established a robust antibody discovery and research platform that enables the creation of unique antibodies, aimed at addressing complex tumor environments and improving patient outcomes. Symphogen’s diverse client base includes pharmaceutical companies and research institutions, with its products mainly distributed in key markets across Europe and North America.In the most recent fiscal year of 2024, Symphogen reported revenue of EUR 69,030,668.30 and an EBITDA of EUR 9,877,436.10. The company generates revenue through partnerships with pharmaceutical companies, engaging in collaborative agreements to co-develop therapies and share the risks and rewards of the development process. Revenue can also be derived from licensing agreements, allowing clients access to Symphogen’s proprietary technologies.Symphogen A/S is poised for future growth through the development of new antibody products and a strategic focus on expanding into additional markets. The company plans to target regions in Asia and North America for market expansion by 2025. Recent funding from the VENTURE DEBT round will be utilized to support these initiatives. Additionally, EW Healthcare Partners has acquired Symphogen A/S, further positioning the company for growth and innovation.

## Funding rounds

- Series E, Jan 31, 2007, $6.6M — Gilde Healthcare
- Series D, Jan 10, 2006, $25M — Essex Woodlands, LD Pensions, Novo Holdings, SLS Invest, Vaekstfonden, Takeda Pharmaceutical
- Series C, Nov 2, 2004, $25M — Essex Woodlands, LD Pensions, SLS Invest, Vaekstfonden, Novo Holdings

## Investors

- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C, Series D
- LD Pensions — Series C, Series D
- SLS Invest (https://capitalatlas.ai/funds/sls-invest) — Series C, Series D
- Vaekstfonden (https://capitalatlas.ai/funds/vaekstfonden) — Series C, Series D
- Novo Holdings — Series C, Series D
- Takeda Pharmaceutical — Series D
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series E